Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
—
−21.93USD
−21.29 MUSD
1.15 M
About Kiromic BioPharma, Inc.
Sector
Industry
CEO
Pietro Bersani
Website
Headquarters
Houston
Employees (FY)
35
Founded
2006
FIGI
BBG00TSG1ZM7
Kiromic Biopharma, Inc. is a clinical stage biotherapeutics company, which engages in DIAMOND AI and discovers, validates, and develops cell and gene therapies with a therapeutic focus on immuno-oncology. The firm is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of gamma delta T-cells to target solid cancers. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck on August 6, 2006 and is headquartered in Houston, TX.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of KRBP is 2.50 USD — it hasn't changed in the past 24 hours. Watch Kiromic BioPharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Kiromic BioPharma, Inc. stocks are traded under the ticker KRBP.
Kiromic BioPharma, Inc. is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.
KRBP stock is 0% volatile and has beta coefficient of 2.87. Track Kiromic BioPharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Kiromic BioPharma, Inc. there?
KRBP earnings for the last quarter are −22.50 USD per share, whereas the estimation was −16.80 USD resulting in a −33.93% surprise. The estimated earnings for the next quarter are −16.80 USD per share. See more details about Kiromic BioPharma, Inc. earnings.
Yes, you can track Kiromic BioPharma, Inc. financials in yearly and quarterly reports right on TradingView.
KRBP stock has fallen by 5.30% compared to the previous week, the month change is a 16.67% fall, over the last year Kiromic BioPharma, Inc. has showed a 50.10% decrease.
KRBP net income for the last quarter is −4.78 M USD, while the quarter before that showed −4.28 M USD of net income which accounts for −11.63% change. Track more Kiromic BioPharma, Inc. financial stats to get the full picture.
Today Kiromic BioPharma, Inc. has the market capitalization of 3.22 M, it has decreased by 10.65% over the last week.
No, KRBP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, KRBP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kiromic BioPharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
KRBP reached its all-time high on Dec 17, 2020 with the price of 555.55 USD, and its all-time low was 0.16 USD and was reached on Oct 12, 2023. View more price dynamics on KRBP chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 2, 2024, the company has 35.00 employees. See our rating of the largest employees — is Kiromic BioPharma, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kiromic BioPharma, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kiromic BioPharma, Inc. stock shows the sell signal. See more of Kiromic BioPharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.